All In Biotech

Drug Trial Radar · NCT04931654

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

136

Actual

Start

Sep 28, 2021

Primary completion

Dec 4, 2024

Study completion Aug 12, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Interventions

  • AZD7789Drug

    anti-PD-1 and anti-TIM-3 bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)Time frame: From time of Informed Consent to 90 days post last dose of study intervention
  2. Number of participants with dose-limiting toxicity (DLT), as defined in the protoocolTime frame: From the first patient until the end of the dose escalation period; approximately 18 months.
  3. Preliminary anti-tumour activity of AZD7789Time frame: From first participant until last participant assessment; a duration of approximately 4 years. Disease assessments will be performed until progression or initiation of another anticancer therapy.

Locations

21 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Atlanta, Georgia

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    New York, New York

  • Research Site

    Nashville, Tennessee

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Beijing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Bordeaux, France

  • Research Site

    Rennes, France

  • Research Site

    Villejuif, France

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Chūōku, Japan

  • Research Site

    Kashiwa, Japan

  • Research Site

    Chisinau, Moldova

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Cordaleo, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.